Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 57 min ago
Peer-reviewedCC BY-NC 4.0International Journal of Nanomedicine

Selenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects

  • Keqian Chen1
  • Shu-Zhi Wang2
  1. 1Department of Clinical Pharmacy, Xiangtan Central Hospital (The Affiliated Hospital of Hunan University), Xiangtan, Hunan, People’s Republic of China
  2. 2Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan, People’s Republic of China
Read full textPDFDOICite

Abstract

Keqian Chen,1 Shu-Zhi Wang21Department of Clinical Pharmacy, Xiangtan Central Hospital (The Affiliated Hospital of Hunan University), Xiangtan, Hunan, People’s Republic of China; 2Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan, People’s Republic of ChinaCorrespondence: Shu-Zhi Wang, Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan, People’s Republic of China, Email [email protected]: Selenium nanoparticles (SeNPs) have emerged as a promising nanomaterial in biomedicine due to their unique physicochemical properties. This review summarizes the research and progress of SeNPs in atherosclerosis (AS) and non-alcoholic fatty liver disease (NAFLD). In the AS model, CS-SeNPs (40 μg Se/kg/day, 10 weeks) significantly reduced the area of aortic plaques (25.1%). Similarly, PM@Se/Rb1 NPs significantly reduced the plaque area of the aortic arch (85→ 20%) and aortic root (79→ 26.5%). In the NAFLD model, various SeNPs improved the area of steatosis, reduced the levels of TC, TG, ALT, and AST, and inhibited inflammation, oxidative stress, and the progression of fibrosis. Unlike previous reviews that focus on a single disease, this review uniquely integrates and compares the therapeutic applications of SeNPs in AS and NAFLD by targeting their common pathological mechanisms. Additionally, we highlight conflicting findings on long-term safety and provide a comparative analysis of different stabilizer formulations. The limitations of the currently available evidence are predominantly derived from cell culture and animal models. Despite encouraging preclinical results, challenges remain regarding long-term safety, optimal stabilizer selection, and translational feasibility. Future directions should prioritize toxicological profiling, large-animal validation, and fibrosis-reversal efficacy to facilitate clinical translation of SeNPs as multi-target nanotherapeutics for chronic disease.Keywords: selenium nanoparticles, nanomedicine, atherosclerosis, non-alcoholic fatty liver disease, antioxidant therapy

Related

  1. Inflammation and wound healing: a comprehensive overview of mechanisms, therapeutic strategies, and translational perspectives
    Yixiao Zhang, Dezhi Guo, Lizhou Song +6
    Biomarker ResearchPeer-reviewedCC BY-NC-ND12 citedSurgery & anaesthesiaOpenAlex
  2. Transendothelial Transport of Low-Density Lipoproteins in Atherosclerosis: Mechanisms of Activation and Possible Therapeutic Targets
    Dmitry Tanyanskiy, Alexander Denisenko
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Surgery & anaesthesiaCrossref
  3. Role of insulin resistance in atherosclerosis: underlying mechanisms and emerging stem cell-based therapeutic strategies.
    Qiuwang Zhang, Yingen Chen, Di Wang +2
    Frontiers in medicinePeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC
  4. Targeting the NLRP3 inflammasome in rheumatoid arthritis fibroblast-like synoviocytes: pathogenic mechanisms, therapeutic strategies, and translational perspectives
    Lunmin Bao, Haibing Dai, Daoming Wang +1
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  5. Posttranslational Modification Cross-Talk in Vascular Cells: Molecular Mechanisms and Therapeutic Implications for Atherosclerosis.
    Weiwei Jiang, Haiping Du
    Cell biochemistry and functionPeer-reviewedCC BYFull textPhysiologyEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{chen2026selenium,
  title = {{Selenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects}},
  author = {Keqian Chen and Shu-Zhi Wang},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  month = oct,
  doi = {10.2147/ijn.s637621},
  url = {https://www.dovepress.com/selenium-nanoparticles-in-atherosclerosis-and-non-alcoholic-fatty-live-peer-reviewed-fulltext-article-IJN},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Selenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects
AU  - Keqian Chen
AU  - Shu-Zhi Wang
PY  - 2026
DA  - 2026/10/01
JO  - International Journal of Nanomedicine
DO  - 10.2147/ijn.s637621
UR  - https://www.dovepress.com/selenium-nanoparticles-in-atherosclerosis-and-non-alcoholic-fatty-live-peer-reviewed-fulltext-article-IJN
AB  - Keqian Chen,1 Shu-Zhi Wang21Department of Clinical Pharmacy, Xiangtan Central Hospital (The Affiliated Hospital of Hunan University), Xiangtan, Hunan, People’s Republic of China; 2Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan, People’s Republic of ChinaCorrespondence: Shu-Zhi Wang, Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan, People’s Republic of China, Email [email protected]: Selenium nanoparticles (SeNPs) have emerged as a promising nanomaterial in biomedicine due to their unique physicochemical properties. This review summarizes the research and progress of SeNPs in atherosclerosis (AS) and non-alcoholic fatty liver disease (NAFLD). In the AS model, CS-SeNPs (40 μg Se/kg/day, 10 weeks) significantly reduced the area of aortic plaques (25.1%). Similarly, PM@Se/Rb1 NPs significantly reduced the plaque area of the aortic arch (85→ 20%) and aortic root (79→ 26.5%). In the NAFLD model, various SeNPs improved the area of steatosis, reduced the levels of TC, TG, ALT, and AST, and inhibited inflammation, oxidative stress, and the progression of fibrosis. Unlike previous reviews that focus on a single disease, this review uniquely integrates and compares the therapeutic applications of SeNPs in AS and NAFLD by targeting their common pathological mechanisms. Additionally, we highlight conflicting findings on long-term safety and provide a comparative analysis of different stabilizer formulations. The limitations of the currently available evidence are predominantly derived from cell culture and animal models. Despite encouraging preclinical results, challenges remain regarding long-term safety, optimal stabilizer selection, and translational feasibility. Future directions should prioritize toxicological profiling, large-animal validation, and fibrosis-reversal efficacy to facilitate clinical translation of SeNPs as multi-target nanotherapeutics for chronic disease.Keywords: selenium nanoparticles, nanomedicine, atherosclerosis, non-alcoholic fatty liver disease, antioxidant therapy
SN  - 1178-2013
SN  - 1176-9114
ER  -